CA2488850A1 - Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine -3 a utiliser dans le traitement ducancer - Google Patents
Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine -3 a utiliser dans le traitement ducancer Download PDFInfo
- Publication number
- CA2488850A1 CA2488850A1 CA002488850A CA2488850A CA2488850A1 CA 2488850 A1 CA2488850 A1 CA 2488850A1 CA 002488850 A CA002488850 A CA 002488850A CA 2488850 A CA2488850 A CA 2488850A CA 2488850 A1 CA2488850 A1 CA 2488850A1
- Authority
- CA
- Canada
- Prior art keywords
- galectin
- terminally truncated
- truncated galectin
- protein
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Marine Sciences & Fisheries (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
L'invention concerne une composition présentant une quantité efficace de galectine-3, tronquée au niveau de son extrémité <I>N</I>-terminale, dans un excipient pharmaceutiquement acceptable ou une quantité efficace d'une séquence d'acide nucléique codant pour la galectine-3, tronquée au niveau de son extrémité <I>N</I>-terminale, dans un excipient pharmaceutiquement acceptable. La présente invention concerne également une méthode de traitement du cancer, consistant à administrer à un patient nécessitant un tel traitement une quantité efficace de galectine-3, tronquée au niveau de son extrémité <I>N</I>-terminale, dans un excipient pharmaceutiquement acceptable ou une quantité efficace d'une séquence d'acide nucléique codant pour la galectine-3, tronquée au niveau de son extrémité <I>N</I>-terminale, dans un excipient pharmaceutiquement acceptable. Cette invention concerne en outre un anticorps, se liant spécifiquement à des ligands glucidiques de la galectine-3, un traitement contre le cancer renfermant une quantité efficace de galectine-3, tronquée au niveau de son extrémité <I>N</I>-terminale, dans un excipient pharmaceutiquement acceptable ou une quantité efficace d'une séquence d'acide nucléique codant pour la galectine-3, tronquée au niveau de son extrémité <I>N</I>-terminale, dans un excipient pharmaceutiquement acceptable.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29697001P | 2001-06-08 | 2001-06-08 | |
US60/296,970 | 2001-06-08 | ||
PCT/US2002/018478 WO2002100343A2 (fr) | 2001-06-08 | 2002-06-10 | Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine-3 a utiliser dans le traitement du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2488850A1 true CA2488850A1 (fr) | 2002-12-19 |
Family
ID=23144316
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002488850A Abandoned CA2488850A1 (fr) | 2001-06-08 | 2002-06-10 | Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine -3 a utiliser dans le traitement ducancer |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1534317A4 (fr) |
AU (1) | AU2002322066A1 (fr) |
CA (1) | CA2488850A1 (fr) |
WO (1) | WO2002100343A2 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7432331B2 (en) | 2002-12-31 | 2008-10-07 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
JP2006522163A (ja) | 2003-04-07 | 2006-09-28 | グリコジェネシス, インク. | ガレクチンアンタゴニストの組成物と使用 |
JP5903270B2 (ja) * | 2008-10-29 | 2016-04-13 | ビージー メディシン, インコーポレイテッド | ガレクチン−3の免疫アッセイ |
CN102488619B (zh) | 2011-12-05 | 2014-08-06 | 上海交通大学 | 连续生产艾塞那肽微球的装置及控制微球释放速度的方法 |
WO2014100703A2 (fr) | 2012-12-20 | 2014-06-26 | Henry Ford Health System | Méthode de traitement de l'insuffisance cardiaque diastolique par inhibition de la galectine-3 |
WO2015085207A1 (fr) * | 2013-12-05 | 2015-06-11 | Texas Tech University System | Galectine-3 pour le traitement du cancer des ovaires |
EP3102247A4 (fr) * | 2014-02-03 | 2017-09-13 | Texas Tech University System | Inhibiteur de galectine 3 (gal-3) associé à des effets anti-myélome et anti-tumeurs solides additifs, à une ostéoclastogenèse et une protection d'organes diminuées lorsqu'il est utilisé en combinaison avec des inhibiteurs du protéasome |
AU2015311857A1 (en) | 2014-09-03 | 2017-03-23 | Genesegues, Inc. | Therapeutic nanoparticles and related compositions, methods and systems |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS62502939A (ja) * | 1985-04-23 | 1987-11-26 | メディカル・バイオロジ−・インスティチュ−ト | 分子クロ−ニングによるIgE結合蛋白質の同定 |
US20020019009A1 (en) * | 1999-12-09 | 2002-02-14 | Roggen Erwin Ludo | High throughput screening (HTS) assays |
AU2001243622A1 (en) * | 2000-03-13 | 2001-09-24 | La Jolla Institute For Allergy And Immunology | Monocyte chemoattractant activity of galectin-3 |
-
2002
- 2002-06-10 AU AU2002322066A patent/AU2002322066A1/en not_active Abandoned
- 2002-06-10 WO PCT/US2002/018478 patent/WO2002100343A2/fr not_active Application Discontinuation
- 2002-06-10 EP EP02756157A patent/EP1534317A4/fr not_active Withdrawn
- 2002-06-10 CA CA002488850A patent/CA2488850A1/fr not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1534317A2 (fr) | 2005-06-01 |
WO2002100343A3 (fr) | 2005-03-17 |
AU2002322066A1 (en) | 2002-12-23 |
WO2002100343A2 (fr) | 2002-12-19 |
EP1534317A4 (fr) | 2005-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7820797B2 (en) | Glycolipopeptide antibodies | |
JP6889199B2 (ja) | p97のフラグメントおよびその使用 | |
US9211345B2 (en) | Glycopeptide and uses thereof | |
JP6676589B2 (ja) | 薬物動態特性の改善されたコンプスタチンアナログ | |
US6770622B2 (en) | N-terminally truncated galectin-3 for use in treating cancer | |
US20150299290A1 (en) | Immunogenic vaccine | |
JP4187277B2 (ja) | グリコシル化し得る抗原結合単鎖タンパク質、それらの生成および使用 | |
US9783578B2 (en) | Immunosuppression modulating compounds | |
CN103096915A (zh) | 免疫抑制调节化合物 | |
CZ304876B6 (cs) | Fragment Aβ vázaný k nosičovému peptidu, farmaceutický prostředek pro prevenci nebo léčení onemocnění spojeného s amyloidními deposity Aβ v mozku pacienta jej obsahující a jeho použití | |
US6238667B1 (en) | Method of affinity cross-linking biologically active immunogenic peptides to antibodies | |
US20060241022A1 (en) | Selectin targeting bioconjugates | |
EA007218B1 (ru) | Предотвращение и лечение амилоидогенного заболевания | |
US20050181987A1 (en) | Compositions and methods for treatment of cancer | |
US6245334B1 (en) | Method of causing selective immunosuppression using HL-60-related lectins | |
JP2008515975A (ja) | 抗癌化合物および方法 | |
JP2002517999A (ja) | 抗血管形成タンパク質およびその使用方法 | |
CA2488850A1 (fr) | Galectine-3, tronquee au niveau de son extremite n-terminale, a liberation prolongee et anticorps aux ligands glucidiques de la galectine -3 a utiliser dans le traitement ducancer | |
US20050032673A1 (en) | Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease | |
WO1994011497A1 (fr) | Procede d'obtention d'une immunosuppression selective a l'aide de lectines apparentees a hl-60 | |
WO1996011700A1 (fr) | Utilisation de substances activatrices de la phospholipase a2 pour reduire les neoplasmes chez les mammiferes | |
EP1627885B1 (fr) | Polypeptide favorisant l'absorption par le systeme digestif | |
CN112292393A (zh) | 双功能血脑疗法 | |
CN106215179A (zh) | 免疫原性疫苗 | |
US6406679B1 (en) | Use of HL-60-related lectins in drug delivery and detection of lectin-expressing cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |